Misonix (Misonix) Cash And Cash Equivalents : $31.05 Mil (As of Jun. 2021)

View and export this data going back to 2019. Start your Free Trial

What is Misonix Cash And Cash Equivalents?

Misonix's quarterly cash and cash equivalents declined from Dec. 2020 ($32.83 Mil) to Mar. 2021 ($30.91 Mil) but then increased from Mar. 2021 ($30.91 Mil) to Jun. 2021 ($31.05 Mil).

Misonix's annual cash and cash equivalents increased from Jun. 2019 ($7.84 Mil) to Jun. 2020 ($37.98 Mil) but then declined from Jun. 2020 ($37.98 Mil) to Jun. 2021 ($31.05 Mil).

Misonix Cash And Cash Equivalents Historical Data

The historical data trend for Misonix's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix Cash And Cash Equivalents Chart

Misonix Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Cash And Cash Equivalents

Get a 7-Day Free Trial

11.56

10.98

7.84

37.98

31.05

Misonix Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash And Cash Equivalents	Get a 7-Day Free Trial															37.98	34.94	32.83	30.91	31.05

Misonix Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Misonix (NAS:MSON) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Misonix Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Misonix's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Misonix (Misonix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

1938 New Highway, Farmingdale, NY, USA, 11735

Website

https://www.misonix.com

Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.

Executives

Paul A Laviolette	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz	officer: Chief Operating Officer	3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton	director	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer	officer: Chief Financial Officer	3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe	director	C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub	officer: Sr. VP Wound	8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis	director, officer: CEO	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker	officer: SVP Sales - Surgical	4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley	officer: President	C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby	director	C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc	10 percent owner	2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p.	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p.	10 percent owner	C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p.	10 percent owner	3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104